Oftalmolojide Botulinum Toksin Uygulamaları

Ayoub N. Botulinum Toxin Therapy: A Comprehensive Review on Clinical and Pharmacological Insights. J Clin Med. 2025 Mar 1;14(6):2021.

Chen S. Clinical Uses of Botulinum Neurotoxins: Current Indications, Limitations and Future Developments. Toxins (Basel). 2012 Oct;4(10):913.

De Maio M. Therapeutic uses of botulinum toxin: From facial palsy to autonomic disorders. Expert Opin Biol Ther. 2008 Jun;8(6):791–8.

Rossetto O, Pirazzini M, Fabris F, Montecucco C. Botulinum Neurotoxins: Mechanism of Action. Handb Exp Pharmacol. 2021;263:35–47.

Trindade De Almeida AR, Secco LC, Carruthers A. Handling botulinum toxins: An updated literature review. Dermatologic Surg. 2011 Nov;37(11):1553–65.

Walker TJ, Dayan SH. Comparison and Overview of Currently Available Neurotoxins. J Clin Aesthet Dermatol. 2014 Feb;7(2):31.

Hexsel D, Rutowitsch MS, De Castro LCM, Do Prado DZ, Lima MM. Blind multicenter study of the efficacy and safety of injections of a commercial preparation of botulinum toxin type a reconstituted up to 15 days before injection. Dermatologic Surg. 2009;35(6):933–40.

Stephan S, Wang TD. Botulinum toxin: Clinical techniques, applications, and complications. Facial Plast Surg. 2011;27(6):529–39.

Klein AW. Complications and adverse reactions with the use of botulinum toxin. Semin Cutan Med Surg. 2001;20(2):109–20.

Özkan SB. Golden Indications and an Overview on the Use of Botulinum Toxin in Strabismus. Turkish J Ophthalmol. 2023 Dec 1;53(6):377.

Alhejaili AL, Alkayyal AA, Alawaz RA, Alshareef EK, Al-Habboubi H. Dose-Effect Relationship of Botulinum Toxin Type A in the Management of Strabismus: A Review. Cureus. 2024 Oct 11;16(10):e71271.

Gaćina K, Lešin M, Sarajčev D, Rotim N. THE EFFECT OF BOTULINUM TOXIN TYPE A IN PATIENTS WITH ESSENTIAL BLEPHAROSPASM. Acta Clin Croat. 2022 Nov 1;61(3):379.

Fang X bo, Xie M shu, Song Z biao, Zhong Z gang, Wang Y, Ou Z lin, et al. Long-term treatment of blepharospasm with botulinum toxin A: a service-based study over a 16-year follow-up in southern China. Neurol Sci. 2020 Mar 1;41(3):645–52.

Deka A, Saikia SP. Lower lid entropion correction with botulinum toxin injection. Oman J Ophthalmol. 2010;3(3):158.

Nava-Castañeda A, Tovilla-Canales JL, Boullosa V, Tovilla-y-Pomar JL, Monroy-Serrano MH, Tapia-Guerra V, et al. Duration of botulinum toxin effect in the treatment of crocodile tears. Ophthal Plast Reconstr Surg. 2006 Nov;22(6):453–6.

Jeffers J, Lucarelli K, Akella S, Setabutr P, Wojno TH, Aakalu V. Lacrimal gland botulinum toxin injection for epiphora management. Orbit. 2021;41(2):150.

Ozturk Karabulut G, Fazil K, Saracoglu Yilmaz B, Ozturker C, Günaydın ZK, Taskapili M, et al. An algorithm for Botulinum toxin A injection for upper eyelid retraction associated with thyroid eye disease: long-term results. Orbit. 2021 Oct 1;40(5):381–8.

Li D, Sun F. Observations on the Efficacy of Two Methods for the Treatment of Upper Eyelid Retraction in Thyroid-Associated Ophthalmopathy. Biomed Res Int. 2021;2021:9514279.

Naik MN, Gangopadhyay N, Fernandes M, Murthy R, Honavar SG. Anterior chemodenervation of levator palpebrae superioris with botulinum toxin type-A (Botox®) to induce temporary ptosis for corneal protection. Eye. 2008;22(9):1132–6.

Tint NL, Saxby EPI, Young SL, Alexander P. A modified transconjunctival technique for botulinum toxin chemodenervation of levator palpebrae superioris for corneal protection. Eye. 2022 Jun 1;36(6):1217–21.

Repka MX, Savino PJ, Reinecke RD. Treatment of Acquired Nystagmus With Botulinum Neurotoxin A. Arch Ophthalmol. 1994;112(10):1320–4.

Tomsak RL, Remler BF, Averbuch-Heller L, Chandran M, Leigh RJ. Unsatisfactory treatment of acquired nystagmus with retrobulbar injection of botulinum toxin. Am J Ophthalmol. 1995;119(4):489–96.

Borba A, Matayoshi S, Rodrigues M. Avoiding Complications on the Upper Face Treatment With Botulinum Toxin: A Practical Guide. Aesthetic Plast Surg. 2021 Feb 1;46(1):385.